PSP Projects Q1: consolidated PAT ₹18.3 Cr on 65% YoY revenue jump, margins recover
PAT +4232% YoY · revenue +64.84% · margins expanding
₹853.47 Cr
+64.84% YoY
₹18.34 Cr
+4232% YoY
2.14%
+2.1pp YoY
₹4.63
PSP Projects opened FY27 with consolidated revenue of ₹853.5 Cr, up 64.8% year-on-year from a weak ₹517.8 Cr in Q1 FY26, and net profit of ₹18.3 Cr against a near-zero ₹0.42 Cr a year ago — a genuine profitability recovery, though the eye-catching YoY PAT multiple is largely a low-base artefact rather than 40x underlying growth. Net margin widened to 2.1% (from 0.1% YoY) and operating margin to roughly 6.4% (year-ago 4.8%), the margin repair management has been guiding toward. There were no exceptional items on either side, so reported and adjusted growth are the same.
Q1 FY-2027 vs prior quarters
Sequentially the print is softer: revenue fell 23.5% and PAT 13.0% versus the seasonally strong ₹1,115.2 Cr / ₹21.1 Cr Q4 FY26 — a normal Q1 slowdown for an EPC contractor whose execution back-loads into the second half, not a deterioration. Finance costs dropped to ₹7.5 Cr from ₹11.2 Cr YoY, consistent with the deleveraging drive; management's FY26-call goal of turning debt-free (aided by Adani group interest-free advances) is the lever meant to lift PAT margins further. Standalone tells the same story (revenue ₹785.3 Cr, PAT ₹15.2 Cr), with the consolidated uplift coming from subsidiary profit of ~₹3.3 Cr.
The stock went into the print at ₹1,012, down 2.1% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
Management reiterates strong guidance for FY27, targeting revenue of INR 4,500 crores and an improved EBITDA margin of 7% to 8%. The company anticipates significant order inflows of INR 6,000-8,000 crores, driven primarily by group projects. A key strategic goal is to become debt-free within the next year, which is exp
— This quarter: met
Against management's own FY27 guidance — revenue ₹4,500 Cr and 7–8% EBITDA margin, backed by an order book that closed FY26 at ₹13,447 Cr (up 85%) — Q1 is on-track but not ahead: ₹853 Cr is ~19% of the annual target (acceptable given H2-heavy execution), while the ~6.4% operating margin still sits below the 7–8% band. No brokerage consensus was available for this small-cap quarter, and the company gives formal annual guidance rather than quarterly. The result confirms, rather than contradicts, the bullish, margin-improvement tone struck on the April concall.
W1
Revenue run-rate vs FY27 guidance of ₹4,500 Cr — Q1 ₹853 Cr needs H2 acceleration to close the gap
W2
EBITDA margin trajectory toward the guided 7–8% (Q1 ~6.4%)
W3
Progress on the debt-free goal — finance costs already down to ₹7.5 Cr from ₹11.2 Cr YoY
Clean digital PDF; unit Rs Lakh converted to Cr. Consolidated PBT 2,824.73L is before JV share; PAT includes +0.31L JV share of profit; no exceptional items and no non-controlling interest. Standalone PAT 15.16 Cr vs consolidated 18.34 Cr (subsidiary PAT ~3.32 Cr). Q1 FY26 base was near-zero profit, so YoY PAT% is a base effect.
Strong revenue growth masks thin margins and execution risks
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 5/10
Grade B
Maintained FY27 revenue target (4,500 Cr) and margin guidance (7–8%); delivered numbers support execution, but thin margins and pending receivables reduce confidence.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 delivered strong 65% revenue growth and expanded order book to ₹13,245 Cr with Adani backing, but NPM collapsed to 2.1% and EBITDA margin fell short of 7–8% guidance. Margin miss blamed on seasonal labor deficit and elevated employee costs; management expects recovery in H2. Key risk: past receivable collection issues (SDB ₹90 Cr, UP Medical ₹100 Cr) and order inflow guidance implicitly downgraded from ₹6,000–8,000 Cr to ₹4,000–5,000 Cr.
₹853.5 Cr
Revenue · +64.8% YoY₹18.3 Cr
Reported PAT · +4232.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Strong 65% YoY revenue growth despite seasonal headwinds
METDelivered 853.5 Cr vs. 518 Cr YoY, confirmed 65% growth. Q1 is seasonally weak.
EBITDA margin 6.4% reflects Q1 labor deficit, expect 7–8% in H2
PartialActual 6.4% EBITDA margin. Employees 5.39% of sales (vs. normal 4–4.5%). Explanation: Apr–May labor shortage, June revenue 319 Cr (higher). Credible but execution risk remains.
NPM improvement from 0.07% to 2.12% is substantial
METVerified: 37 lakh to 18.3 Cr YoY. But 2.12% NPM is VERY thin; breaks down to ₹55 Cr EBITDA on ₹853 Cr revenue.
Order book 13,245 Cr provides multi-year visibility; 70% from Adani
METOrder book confirmed; 70% within-group (Adani), 30% external. Concentration risk high if Adani orders slow.
Order inflows ₹4,000–5,000 Cr FY27 remain in prior range
OVERSTATEDPrior guidance ₹6,000–8,000 Cr. MD now says ₹4,000–5,000 Cr. Implicit downgrade from 6,000–8,000 to 4,000–5,000.
Debt-free within a year (prior FY26 call guidance)
MISSNow guided as 2–3 quarters (by early 2027). Long-term debt ₹38 Cr, short-term ₹217 Cr; working capital facilities still utilized ₹844 Cr. Slipping timeline.
Earnings quality
What changed since the last call
Order inflow guidance downgraded
DowngradePrior FY26 calls: ₹6,000–8,000 Cr expected. MD now implies ₹4,000–5,000 Cr FY27. Soft language ('will be in same range') masks a 25% reduction.
Debt-free timeline slipped
DowngradeFY26 guidance: 'within one year' (by June 2027). Now: 'within 2–3 quarters' (Oct–Dec 2026). Still on track but not ahead of plan.
Margin recovery pushed to H2
NeutralEBITDA margin 6.4% (vs. 7–8% guidance). Management attributes to seasonal labor deficit; expects recovery as June performance (₹319 Cr revenue) validates acceleration into core construction phase.
Employee team scaled 1.5–2x from prior year
UpgradeHeadcount 2,400 → 2,600. Employee cost 5.39% of sales (temporary excess to execute scaled order book). Management targets return to 4–4.5% as utilization improves.
The Q&A
Analysts pressed hard on margin credibility (3 questions). MD defended with detailed labor-cost breakdown but offered no guardrails. Receivables (SDB, UP Medical) mentioned without follow-up. One analyst accepted soft order inflow guidance without pushing for explicit prior-guidance retraction.
Revenue guidance reaffirmation — Shravan Shah, Dolat Capital
AnsweredYes, will be more than 25% on average, between ₹4,400–4,500 Cr. Remain in same line.
EBITDA margin timing — Shravan Shah, Dolat Capital
AnsweredH2 only due to seasonal labor deficit. April–May sales weak, June ₹319 Cr shows acceleration. If loss due to labor deficit factored in, EBITDA above 7%. Better in Q3–Q4.
Order inflow run-rate — Shravan Shah, Dolat Capital
PartialProbably same range, ±₹400–500 Cr, remains ₹4,000–5,000 range. Projects under discussion for Q2–Q3.
Working capital trajectory — Shravan Shah, Dolat Capital
AnsweredYes, we can expect so.
Mumbai project execution status — Balasubramanian, Arihant Capital
AnsweredMahim: raft foundation done, first basement floor underway. Matunga: sheet piling ongoing before excavation.
Mobilization advance terms — Balasubramanian, Arihant Capital
AnsweredThe whole amount is interest-free.
Commonwealth project timeline — Dhananjay Mishra, Centrum Broking
AnsweredNo clear timeline yet; control room just started. Probably next quarter heard. Not in FY27 order inflow guidance (government projects counted in bid pipeline only).
UP Medical receivable resolution — Dhananjay Mishra, Centrum Broking
AnsweredThree projects near EOT signing. Discussion in Lucknow last Monday. Expect EOTs by weekend/first week Aug. Money due. Account close end-Aug/mid-Sep. Unbilled ₹60 Cr + receivable ₹40 Cr will materialize.
EBITDA margin guidance upside — Ayush Saboo, Choice Institutional Equities
AnsweredH2 only. As execution speeds up in next few quarters, should be in better position to go beyond 7–8%.
SDB receivable update — Vaibhav Shah, JM Financial
DodgedNo clarity. Called for discussion with top management/board. Visiting next week. They reached out to meet but unknown positive direction. Outstanding ₹90 Cr.
Margin guidance scope (full-year vs. H2) — Vaibhav Shah, JM Financial
PartialShould be for full year. Once execution speed picks up in next quarters, should be in better position to go beyond 7–8%.
Consolidated vs. standalone revenue — Vaibhav Shah, JM Financial
AnsweredSubsidiary company executes ₹80 Cr miscellaneous Adani projects. All future guidance will be on console basis only.
Dharavi order book composition — Vishal Periwal, PL Capital
AnsweredTwo projects, ₹3,000 Cr. At ₹10–12 lakh/house (₹3,000–3,500 per sq ft), equals 30,000–32,000 houses out of total 2 lakh houses.
Dharavi follow-on opportunities — Vishal Periwal, PL Capital
AnsweredDepends on performance on current two. Foundation complexity high. Once stable on these, can always start new site. Right of first refusal if perform well.
Labor deployment scale — Vishal Periwal, PL Capital
AnsweredDifficult to compare (project-specific). Currently 16,000–17,000 needed, almost full. Peak could add 3,000–4,000 more in next 1–2 quarters as activities diversify.
Inflation impact on cost-plus contracts — Jainam Jain, Dam Capital
AnsweredMost Adani projects are pass-through cost (no impact). 30% external book (INR 5,500–6,000 Cr older projects) mostly complete. Few activities at SMC & RVNL impacted by aluminum/copper inflation; minor.
Segment diversification (new verticals post-Adani) — Jainam Jain, Dam Capital
AnsweredNo. Focus on buildings only (industry, data center, commercial, hotel, hospital). Not infrastructure or non-building work.
Geographic expansion plans — Rushabh, RBSA Investment
AnsweredNo. Focusing on Gujarat & Mumbai only. 25% non-Adani, 70–75% Adani target. Sufficient visibility for 2 years, not entering new regions yet.
Team capability scaling — Rushabh, RBSA Investment
AnsweredEmployee expense up (building team to 1.5–2x from last year). Strengthening to get more Adani orders and deliver on time.
Data center segment opportunity — Jainam Shah, Equirus Securities
PartialNot focused on Mumbai/Visakhapatnam data centers yet. Dholera (Gujarat) has two lands (data center + defense). Could come later. MediCity & housing projects (Mundra, Ahmedabad) starting soon.
Precast segment contribution — Urviben Patel, Infinite Wealth Advisors
PartialNo separate revenue tracking; embedded in project revenue. Plant capacity ₹200 Cr/year, executing ₹150–200 Cr. Margin same as overall business (Adani projects only, no other customers).
Dharavi house-count and project sizing — Shravan Shah, Dolat Capital (repeat)
AnsweredLesser number. ₹3,000 Cr, ₹10–12 lakh per house = 30,000 houses (out of 2 lakh total). Two projects building 30,000–32,000 houses now.
Tax rate normalization — Shravan Shah, Dolat Capital (repeat)
AnsweredSlightly higher due to non-deductible expenses (permanent difference). Will remain elevated vs. 25%.
Cash balance trajectory — Shravan Shah, Dolat Capital (repeat)
AnsweredYes, same level, slightly higher.
Cost-plus formula on Adani projects — Sanjay Kohli, Goldstone Capital
AnsweredCost-plus percentage on overall project cost (materials, labor, overhead). Not separate per-material margin. Total EBITDA level: Adani projects 6–7%, PSP projects 8–9%. Cost-plus effectively 7% EBITDA. Item-rate contract; material base rate quoted, actual difference paid in bill.
Cost-plus range variability — Sanjay Kohli, Goldstone Capital
AnsweredAlways 1–2% gap in execution. Standardized by project type. Mumbai +3%, Mundra +1.5%. Overhead varies by project performance (can save 1–1.5% if project runs fast).
Guidance
FY27 ₹4,400–4,500 Cr (20%+ growth)
HighOn track. Q1 seasonally weak; accelerating from June baseline. Order book ₹13,245 Cr supports full-year execution >₹4,000 Cr.
EBITDA margin 7–8% (H2 focus, full year aspiration)
MediumQ1 at 6.4% due to seasonal labor deficit & elevated employee costs. Management claims 1% margin leakage from April–May underperformance. Credible recovery if June acceleration sustains.
Employee costs normalize to 4–4.5% of revenue from current 5.39%
MediumTeam expansion (2,400 → 2,600) and April increments temporary. Normalization depends on higher absolute revenue.
Capex 3–4% of revenue
HighQ1 delivered ₹28 Cr (3.3%). MD confirms 3–4% range on average; specific large projects may spike slightly.
Risks the call surfaced
Customer concentration
High70% of order book from Adani Group. ~45% of Q1 revenue from Adani. If Adani Group orders slow or investment cycle contracts, PSP exposed to ~40% revenue drop.
Margin credibility
HighNPM at 2.1% (₹18.3 Cr on ₹853.5 Cr). EBITDA 6.4% below 7–8% guidance. Employee costs still 5.39% (vs. 4–4.5% normal). If labor inflation persists or execution slows, margins compress further.
Receivable collection
MediumSDB receivable ₹90 Cr (stuck; MD visiting next week, no timeline). UP Medical ₹100 Cr (₹60 Cr unbilled, ₹40 Cr receivable) expected to close by mid-Sep 2026. Combined ₹190 Cr at risk if customers delay further.
Execution capability
MediumQ1 saw labor deficit in Apr–May; June recovered but dependent on sustained availability. Dharavi project (30,000+ houses) is largest yet; any execution slip could damage 'right of first refusal' for phase 2. SMC & RVNL impacted by aluminum/copper inflation.
Guidance credibility
MediumPrior FY26 guidance: ₹6,000–8,000 Cr order inflows. Current call implies ₹4,000–5,000 Cr. MD used soft language ('same range') but new numbers are lower. If H2 misses even ₹4,000–5,000 Cr target, credibility dents further.
Management
Score 6/10. Clear on execution updates & project-level details. Defensive on margin misses; used technical explanations (seasonal labor deficit, employee scaling) to justify shortfalls. Evasive on SDB receivable (no timeline). Met revenue growth target (65% YoY). Missed EBITDA margin guidance (6.4% vs. 7–8%). Implicit downgrade on order inflows (₹6,000–8,000 → ₹4,000–5,000). Past receivable collection issues (SDB, UP Medical) not fully resolved.
1 · Q2–Q3 FY27
Labor normalization & H2 margin recovery to 7–8% EBITDA target
2 · Aug–Sep 2026
UP Medical ₹100 Cr receivable materialization; SDB ₹90 Cr resolution
3 · H2 FY27
Commonwealth Games Ahmedabad tender (uncertain timing, not in FY27 order inflow guidance)
Key risk: past receivable collection issues (SDB ₹90 Cr, UP Medical ₹100 Cr) and order inflow guidance implicitly downgraded from ₹6,000–8,000 Cr to ₹4,000–5,000 Cr.
Growth on Paper, Execution Risk in the Margins
Revenue jumped 65% and the order book expanded to ₹13,245 crore, but thin 2.1% net margins and slipping guidance cast doubt on whether PSP can execute profitably on the Adani pipeline.
₹18.3 Cr
+4232% YoY (off ₹0.37 Cr base)
2.1%
vs. 7–8% EBITDA guidance
₹13,245 Cr
+103% YoY, 3+ years visibility
PSP's Q1 result is a study in divergence. On the headline — 65% revenue growth, nearly a five-figure PAT jump — it reads like a breakout. But the profit growth is inflated by a near-zero prior-year base (₹0.37 crore), and the real number sits at 2.1% net margin on ₹853.5 crore of revenue. That's a ₹18.3-crore PAT on a ₹853-crore topline. Razor-thin. Add in the fact that EBITDA margin came in at 6.4% (versus 7–8% guidance) and guidance on order inflows has quietly tightened by 25%, and the quarter begins to look less like strength and more like an execution contractor caught between large orders and minimal pricing power.
The margin story: seasonality or structural?
Management blames Q1's 6.4% EBITDA margin on seasonal factors: April and May are traditionally weak in the construction cycle, and labor was scarce both months at ₹270 crore revenue each. June jumped to ₹319 crore, suggesting acceleration back into the seasonal norm. Employee costs are elevated at 5.39% of sales (versus 4–4.5% normalized) due to team expansion to execute the enlarged Adani pipeline; employee expense jumped ₹11 crore year-over-year. The explanation is plausible: if June's pace holds into H2, and labor normalization kicks in, then 7–8% EBITDA is achievable. But here's the risk: this is a promise anchored on execution, not a proven trend. On-call, analysts pressed hard on margin credibility (three separate Q&A exchanges), and management had no guardrails to offer beyond the seasonal story.
Strong 65% YoY revenue growth despite Q1 seasonality
₹853.5 Cr vs. ₹518 Cr prior year. Q1 is structurally weak (Apr–May slow), June ₹319 Cr shows recovery.
Supported
6.4% EBITDA reflects seasonal labor deficit; expect 7–8% in H2
Employee costs 5.39% vs. normal 4–4.5%. Team expanded for Adani pipeline. June momentum suggests recovery potential.
Partial (credible but unproven)
Order book ₹13,245 Cr provides multi-year visibility
Order book confirmed; 70% within-group (Adani), 30% external. Concentration is extreme.
Supported (with caveat)
NPM improvement from 0.07% to 2.12% is substantial
Yes: ₹0.37 Cr → ₹18.3 Cr. But 2.1% NPM is still razor-thin; any cost shock erases profit.
Supported (but thin absolute level)
Order inflows ₹4,000–5,000 Cr FY27 remain in prior range
Prior FY26 guidance: ₹6,000–8,000 Cr. New implied guidance: ₹4,000–5,000 Cr. MD used soft language ('same range') to mask 25–33% downgrade.
Overstated (guidance downgrade)
Debt-free within a year (FY26 call guidance)
Now guided as 2–3 quarters (by Q3–Q4 FY27). Prior target was within 1 year from prior call; new timeline has slipped approximately 1 quarter.
Contradicted (slipping timeline)
What changed on this call
Order inflow guidance implicit downgrade from ₹6,000–8,000 Cr (FY26 call) to ₹4,000–5,000 Cr (now)
Debt-free timeline regressed; now guided as 2–3 quarters versus prior 'within one year'
EBITDA margin recovery pushed to H2; Q1 miss blamed on seasonal Apr–May weakness
Employee cost base elevated at 5.39% of sales (vs. 4–4.5% normal); normalization dependent on higher volumes
SDB receivable (₹90 Cr) unresolved; MD visiting next week with no resolution timeline
UP Medical receivable (₹100 Cr) expected to materialize by end-Aug/mid-Sep
The street's read: pop and fade
PSP's stock traded up 2.83% on day 1 post-result (delivery 46%, solid conviction), then faded to –1.72% by day 3. The initial relief suggests the market bought the revenue beat and large order book at face value; the fade signals reassessment of receivable collection risk (₹190 Cr stuck or uncertain), Adani concentration (70% order book exposure), and the implicit guidance downgrades. The stock is down 18% from its all-time high of ₹1142.1, sitting at ₹934.7 below its SMA20 (₹1032.72) and SMA50 (₹969.74) but above its SMA200 (₹840.9) — a neutral trend with no clear directional conviction. RSI at 31.6 is not yet oversold, suggesting room to test lower. Critically, FII holdings have trimmed to 1.92% (down 0.57 percentage points quarter-over-quarter), while promoters remain stable at 68.82% with no insider selling — a mismatch that suggests institutions are cautious despite the order book story and believe the execution risk deserves a discount.
The bull-bear ledger
Order book of ₹13,245 Cr (3+ years revenue visibility); Adani backing reduces execution risk on large, complex projects
FY27 revenue target of ₹4,400–4,500 Cr (20%+ growth) on track; Q1 base supports full-year delivery at ₹220–230 Cr/quarter average
Dharavi redevelopment (₹3,000 Cr, 30,000–32,000 houses; 23% of order book); right-of-first-refusal on phase 2 (200k houses total) if executed well
Debt-free path on track (₹255 Cr net debt now; ₹38 Cr LT + ₹217 Cr ST); interest cost elimination to boost PAT margins by ~25–30 bp
Net profit margin improved from 0.07% to 2.1% YoY; directionally positive despite weak prior base
Adani Group concentration at 70% of order book; ~45% of Q1 revenue from Adani; zero exposure diversification despite intent to reach 25% non-Adani
EBITDA margin (6.4%) missed guidance (7–8%); recovery to H2 unproven; employee cost scaling structural risk until volumes scale
Net profit margin at 2.1% is razor-thin; any cost shock, execution delay, or receivable slip erases PAT to near-zero
Receivable collection risk: SDB ₹90 Cr (stuck, no timeline), UP Medical ₹100 Cr (expected by Sep). Combined ₹190 Cr material to cash flow
Order inflow guidance downgraded from ₹6,000–8,000 Cr to ₹4,000–5,000 Cr (25–33% cut); soft language masks retreat
Guidance credibility dented: margin miss, order downgrade, debt-free slip — management re-planning, not over-delivering
Risks ranked by holder concern
Adani Group concentration — 70% of order book, ~45% of Q1 revenue
HighIf Adani Group's investment cycle slows or capex policy shifts, PSP loses 40–45% of its revenue run-rate overnight. No near-term diversification roadmap offered; external order book only ₹3,900 Cr (30% of total).
Razor-thin net margin (2.1%) — no room for cost overruns or price concessions
High₹18.3 Cr PAT on ₹853.5 Cr revenue. Labor inflation, material cost shocks, or execution delays compress PAT to near-zero. Pass-through cost contracts on Adani work (6–7% EBITDA) cap upside; leverage works both ways.
Receivable collection: SDB ₹90 Cr + UP Medical ₹100 Cr
Medium₹190 Cr at risk. SDB timeline unknown (MD visiting next week). UP Medical expected by Sep but historical lag on both projects shows precedent. Cash position (₹400+ Cr) covers exposure but resolution timeline unknown.
Margin recovery unproven — 7–8% EBITDA guidance aspiration for H2 only, not Q2
MediumQ1 miss blamed on seasonal Apr–May weakness + employee cost scaling. If structural factors persist (labor inflation, fixed overhead base), recovery fails and FY27 EBITDA misses guidance. Credibility already dented.
Dharavi execution risk — 'right of first refusal' conditional on flawless performance
Medium₹3,000 Cr of ₹13,245 Cr order book (23%) on two Dharavi projects now. Foundation complexity is high; material cannot be replicated easily. Any slip damages credibility for phase 2 follow-on (200k houses total opportunity).
Order inflow guidance downgrade — implicit ₹6k–8k → ₹4k–5k Cr cut already baked in
MediumQ1 saw ₹630 Cr orders (₹2.5 Cr annualized pace, below new ₹4k–5k target). If H2 misses even the revised target, guidance credibility collapses and FY27 revenue target misses.
What to watch next
1 · H2 EBITDA margin delivery (7–8% target) — or structural thinness?
Q2–Q3 results will show whether 6.4% was seasonal or a sign that the pass-through cost model cannot achieve guidance. If margins remain below 7%, FY27 EBITDA misses guidance and FY28 target comes into question. June baseline (₹319 Cr revenue) and labor availability are the swing factors.
2 · Receivable resolution: SDB next week, UP Medical by end-Aug/mid-Sep
₹190 Cr at stake. If both resolve on schedule, cash position strengthens and debt-free timeline holds. If either slips beyond Sep, working capital deteriorates and can constrain growth capex or dividend capacity.
3 · Order inflow run-rate: H2 FY27 execution against revised ₹4k–5k Cr target
Q1 saw ₹630 Cr (₹2.5 Cr annualized, below prior ₹6k–8k guidance). If H2 sees <₹2k Cr annualized run-rate, the ₹4k–5k FY27 target misses and FY28 guidance faces risk. Bid pipeline is ₹6.2k+ Cr but mostly Adani-linked (concentration risk).
The debate
PSP delivered a headline beat on revenue (65% YoY growth, ₹13,245 Cr order book), but the real story is buried in the margins and the reset of guidance. A 2.1% net profit margin leaves zero room for error, and slipped guidance on order inflows and debt-free timing signal management is re-planning, not over-delivering. The stock is down 18% from its all-time high, FII have trimmed, and institutions are cautious. For holders, the next two quarters hinge on three catalysts: (1) Can H2 EBITDA margin hit 7–8%, or is 6.4% structural? (2) Will receivable resolution (SDB, UP Medical) hold to timeline? (3) Can order inflow run-rate hit even the revised ₹4k–5k Cr target? If all three click, risk/reward tilts back toward the bull case. For now, hold and watch execution — the number to track is organic EBITDA margin in Q2 and whether June's ₹319 Cr revenue pace sustains into Q3.